| Document |
Document Title |
|
WO/2024/022495A1 |
This disclosure provides anti-MerTK antibodies, variants thereof and humanized versions. The newly disclosed antibodies exhibited high affinity to the MerTK protein and can be used to treat cancers, in particular solid tumors.
|
|
WO/2024/025264A1 |
The present invention generally relates to a stem cell-derived extracellular vesicle (EV) comprising a signal regulatory protein (SIRP) and a method for preventing or treating cancer and/or inflammatory disease, condition, or symptom by ...
|
|
WO/2024/026224A1 |
The present disclosure relates to methods, uses, compositions, and kits for improving muscle mass, muscle strength, or muscle function or for reducing fatigue, pain, or obesity in a subject using testosterone or testosterone derivative a...
|
|
WO/2024/021826A1 |
Disclosed are a pharmaceutical composition for treating cancerous pain and a preparation method therefor. The pharmaceutical composition is prepared from the following ingredients: 15-20 parts by weight of unprocessed Aconiti Lateralis R...
|
|
WO/2024/023727A1 |
A compound having the structures: Formulae (Ia) or (Ib) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein; R selected from the group cons...
|
|
WO/2024/024915A1 |
Provided is a technique for preventing or treating a periostin-mediated disease and pruritus associated with the disease. The present invention relates to, for example, a prophylactic or therapeutic agent for a periostin-mediated disease...
|
|
WO/2024/023550A1 |
The invention entitled "Malt supplement Containing Oleocanthal, with Anti- inflammatory, Antioxidant and Anti-cancer Properties" is in the field of extracting and formulating a compound used in food, pharmaceutical, and supplement indust...
|
|
WO/2024/022009A1 |
The present disclosure provides a nanoprotein degradation tool, use thereof, and a preparation method therefor. The nanoprotein degradation tool comprises: one or a plurality of combinations of a first degradation tool, a second degradat...
|
|
WO/2024/026109A1 |
The disclosed technology relates generally to compositions, methods, and system for utilizing paraxanthine alone and in combination for use in enhancing immune function and/or inhibiting inflammation through administration of a paraxanth...
|
|
WO/2024/026081A1 |
The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
|
|
WO/2024/022234A1 |
A use of a compound represented by formula (I) in the preparation of a drug for treating BTK-related diseases comprising diseases of the central nervous system, which belongs to the technical field of chemistry in medicine. The compound ...
|
|
WO/2024/019597A1 |
The present invention provides: a novel heterocyclic compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a disease related to autotaxi...
|
|
WO/2024/020517A1 |
Provided herein are compounds of formula (II) and formula (I) that are inhibitors of QPCTL and QPCT: (II) & (I) Also provided are pharmaceutical compositions comprising the compounds, as well as the compounds for use in methods for the t...
|
|
WO/2024/017880A1 |
A series of substituted imidazo[l,2-b][l,2,4]triazine derivatives of Formula (I) as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments,...
|
|
WO/2024/017981A1 |
The present invention refers to a composition for use in the prevention and/or treatment of diseases mediated by TLR4, IL1R, COX1/2 and/or RBP4, preferably inflammatory diseases such as Osteoarthritis (OA) or other diseases, such as infe...
|
|
WO/2024/019519A1 |
The present invention relates to a pharmaceutical composition, comprising iCP-NI, for treating or preventing a cytokine storm or inflammatory diseases, which was developed into a patient-friendly inhalation formulation so that a wider va...
|
|
WO/2024/018242A1 |
The present invention provides binding molecules, particularly antibodies which bind to the IL-12Rβ2 and gp 130 subunits of the IL-35 receptor (IL-35R). The binding molecules are preferably able to act as agonists of the IL-35R. The inv...
|
|
WO/2024/020170A1 |
Provided herein are compounds which can act agonists of the aryl hydrocarbon receptor (AHR). Further disclosed herein are methods for treating inflammatory and autoimmune diseases and disorders, such as diseases or disorders of the gastr...
|
|
WO/2024/019495A1 |
The present invention relates to a pharmaceutical composition for treating or preventing atopic dermatitis, the pharmaceutical composition comprising iCP-NI. The pharmaceutical composition makes it possible to administer iCP-NI, previous...
|
|
WO/2024/016630A1 |
A pharmaceutical composition of diltiazem hydrochloride. The pharmaceutical composition is preferably gel and composed of diltiazem hydrochloride and adjuvants; the adjuvants comprise propylene glycol, benzoic acid and a gel matrix; the ...
|
|
WO/2024/016935A1 |
The present invention belongs to the field of functional emulsions. Disclosed is a method for improving the embedding rates of ginsenosides Rg3 and CK and the stability of a nanoemulsion. The method for improving the embedding rates of r...
|
|
WO/2024/019661A1 |
The present disclosure concerns a method of promoting the ubiquitination of MK2 protein, comprising contacting the MK2 protein with a compound of Formula (I) or a salt, solvate, stereoisomer or prodrug thereof. The present disclosure als...
|
|
WO/2024/018423A1 |
The disclosure relates to compounds of formula (I) comprising a pyrrole or imidazole core, and pharmaceutically acceptable salts and compositions of such compounds. The compounds disclosed are useful as anti-inflammatory and/or other the...
|
|
WO/2024/017227A1 |
Provided is a cannabinoid receptor compound as represented by formula I. The compound has a good ability to bind to the human CB2 receptor, and exhibits good agonistic activity and high selectivity on the CB2 receptor. Consequently, said...
|
|
WO/2024/020197A1 |
The present disclosure provides pharmaceutical compositions comprising a microorganism capable of expressing one or more enzymes that convert salicin to saligenin, and salicin, or a pharmaceutically acceptable salt thereof. The present d...
|
|
WO/2024/020084A1 |
Provided herein are compounds and compositions thereof for modulating IRAK4. In some embodiments, the compounds and compositions are provided for treatment of inflammatory or autoimmune diseases.
|
|
WO/2024/019133A1 |
Provided is a multilayered enteric rigid capsule configured of a first layer, which does not have enteric properties, and a rigid-capsule second layer, which has enteric properties. The multilayered enteric rigid capsule comprises a cap ...
|
|
WO/2024/017383A1 |
Provided are an anti-MCT1 antibody and use thereof. The MCT1 antibody and a humanized antibody thereof have high neutralization activity and high selectivity, can efficiently block the function of MCT1, and show good therapeutic activity...
|
|
WO/2024/020589A1 |
An animal treatment product is described and discussed. An animal treatment product can include an animal food product and a cellular energy inhibitor composition combined with the animal food product, wherein the cellular energy inhibit...
|
|
WO/2024/017915A1 |
The present technology relates to a polypeptide comprising at least three immunoglobulin single variable domains (ISVDs). In particular, the present technology relates to a polypeptide comprising an optimized ISVD binding to fractalkine ...
|
|
WO/2024/020333A2 |
Disclosed is a class of kinase inhibitors. Related pharmaceutical compositions and methods of making and using the kinase inhibitors are also disclosed.
|
|
WO/2024/020221A1 |
Bifunctional compounds, which find utility as modulators of non-receptor tyrosine kinase 2 (TYK2), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a moiety that binds to the ce...
|
|
WO/2024/012387A1 |
A use of a composition comprising an Artemisia annua extract and a water-soluble component in fighting skin allergies, inflammation, and/or irritation, and a use in the preparation of a dermatological topical agent for fighting skin alle...
|
|
WO/2024/011279A1 |
A process for controlling the produc on of urease by biofilm forming bacteria by treatment with N- acetyl cysteine (NAC). A process of preven ng catheter bacterial encrusta on by treatment with NAC. A process of inhibi ng the urease sec...
|
|
WO/2024/011771A1 |
A composition for protecting gastrointestinal mucosa, resisting Helicobacter pylori and promoting gastrointestinal peristalsis, comprising the following components in parts by weight: 0.8-1 parts of Curcumae longae rhizoma extract, 1.6-2...
|
|
WO/2024/012470A1 |
The present invention provides a use of an adamantane nitrate compound or a pharmaceutically acceptable salt thereof in preparation of a drug and in prevention and treatment of cytokine storm. It is found in experiments that the adamanta...
|
|
WO/2024/015512A1 |
Provided are compounds, compositions, and methods of repolarizing a tumor associated macrophage (TAM), reducing macrophage-mediated inflammation, and treating a disease. A compound or pharmaceutical composition may be administered to a s...
|
|
WO/2024/013306A1 |
The present invention relates to a composition comprising the compound of formula (I) or a stereoisomer thereof, in particular amarouciaxanthin A acetate as well as their medical and cosmetic uses.
|
|
WO/2024/014885A1 |
The present invention provides a novel compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. With an excellent inhibitory activity against PIKfyve, the novel compound of the...
|
|
WO/2024/011883A1 |
The present invention relates to a WEE1 inhibitor, preparation therefor and a use thereof. The structure of the WEE1 inhibitor is represented by formula (I). The present invention relates to a compound of formula (I), or a stereoisomer t...
|
|
WO/2024/007070A1 |
Ti3C2Tx MXene nanosheets were enriched with biologically active surface groups, including carboxyl, hydroxyl, and fluorine. MXene interacted with human ECs and downregulated the expression of genes involved in alloantigen presentation, a...
|
|
WO/2024/009324A1 |
The present invention provides the novel prodrugs of cannabidio-type phytocannabinoids having the general Formula A and its process thereof, where one or both the hydroxyl groups are attached to the other counter parts through ester bond...
|
|
WO/2024/009268A1 |
The present disclosure includes cationic carrier units comprising (i) a water-soluble polymer, (ii) a positively charged carrier, (iii) a hydrophobic moiety, and (iv) a crosslinking moiety, wherein when the cationic carrier unit is mixed...
|
|
WO/2024/008597A1 |
The present invention relates to a fermentation product obtained by a fermentation process of at least one bacterial strain in the presence of at least one vegetable extract. The fermentation product of a bacterial may comprise alimentar...
|
|
WO/2024/010015A1 |
Compounds represented by general formula (1), the compounds having strong inhibitory action against mPGES-1 and being useful as active ingredients for pharmaceuticals for the treatment of inflammation and the like.
|
|
WO/2024/010935A1 |
Disclosed are pharmaceutical compositions having a portion of ketamine and/or aspirin for intraoral release and another portion of ketamine and/or aspirin for gastrointestinal release. The disclosed formulations and related administratio...
|
|
WO/2024/007629A1 |
The present invention relates to the field of plant trypsin inhibitors, and provides a polysaccharide trypsin inhibitor and a preparation method therefor. The polysaccharide trypsin inhibitor is obtained by separating and purifying massa...
|
|
WO/2024/010959A1 |
Novel compounds and methods of using the compounds are provided herein. The compounds include novel carbon analogs of pyranose derivatives discovered to have Toll- like receptor 4 (Tlr4) inhibitory activity. The methods provide for treat...
|
|
WO/2024/011178A1 |
Embodiments of the present disclosure recite methods of treating many diseases, such as inflammatory diseases, cancers, cardiovascular diseases, diabetes and obesity or conditions within a patient in need of such treatment by administeri...
|
|
WO/2024/010353A1 |
The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases comprising a compound of chemical formula 1, and to a cosmetic composition comprising the compound. By comprising the compound...
|
